argenx Clinical Trial Pipeline — 56 Active Studies

Phase 1: 7, Phase 2: 15, Phase 3: 24, Other: 10

argenx has built one of the most productive clinical platforms in autoimmune disease through its ABDEG technology — engineered antibodies that enhance FcRn-mediated IgG catabolism, reducing pathogenic autoantibody levels. Efgartigimod (Vyvgart, Vyvdura) is the lead asset: a first-in-class FcRn antagonist approved in generalized myasthenia gravis (gMG), primary immune thrombocytopenia (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP), and pemphigus vulgaris. Efgartigimod's mechanism — reducing all IgG subclasses including pathogenic autoantibodies — positions it as a platform therapy across any antibody-mediated autoimmune disease. argenx is systematically expanding efgartigimod into additional indications including thyroid eye disease, Sjögren's disease, multifocal motor neuropathy (MMN), spinal muscular atrophy (SMA), and Lambert-Eaton myasthenic syndrome (LEMS). Empasiprubart (ARGX-117), targeting complement C2, represents the company's second platform — entering Phase 3 in MMN and other complement-mediated diseases.

• Neuromuscular disease (myasthenia gravis, CIDP, MMN, LEMS)
• Autoimmune disease (ITP, pemphigus, thyroid eye disease, Sjögren's)
• FcRn-mediated IgG reduction (efgartigimod platform)
• Complement inhibition (empasiprubart, C2 targeting)
• Rare pediatric diseases (SMA, congenital myasthenic syndrome)
• Neonatal medicine (antibody-mediated neonatal disease)

• Efgartigimod (Vyvgart IV / Vyvdura SC) — FcRn antagonist, gMG/ITP/CIDP/pemphigus
• Efgartigimod subcutaneous — next-gen delivery, multiple indications
• Empasiprubart (ARGX-117) — anti-C2 complement inhibitor, MMN and others
• ARGX-119 — anti-C2, neuromuscular (earlier-stage)
• ARGX-118 — IgE-FcRn modulator (allergic disease)
• ARGX-220 — antibody-mediated rejection

argenx is registering new efgartigimod trials across autoimmune conditions on a near-monthly basis — each new indication registration represents a potential $1B+ market opportunity. Their trial data in CIDP (which showed unprecedented response rates) has set the bar for future FcRn inhibitor approvals. Competitors (UCB's rozanolixizumab, Johnson & Johnson's nipocalimab) are tracking argenx's trial expansions closely.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to argenx's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.

• Sponsor normalization: argenx may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.